文档下载 文档下载导航
设为首页 | 加入收藏
搜索 请输入内容:  
 导航当前位置: 文档下载 > 所有分类 > 医药卫生 > Estimated Dates of Possible First Time Generic, Rx-to-OTC Market Entry
侵权投诉

Estimated Dates of Possible First Time Generic, Rx-to-OTC Market Entry

未来专利过期的药品清单

Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…

Estimated Dates of Possible First Time Generic/ Rx-to-OTC Market Entry

2009 US Retail Sales:

(in millions)^

Year

2010 2010 2011 2011 2011 2011 2011 2011

Period

4Q (Nov) 4Q (Dec) 1Q (Jan) 1Q (Mar) 2Q (Apr) 2Q (Apr) 2Q (Apr) 2Q (Apr) 2Q (Jun) 2Q (Jun) 3Q (Jul) 4Q (Oct) 4Q (Nov) 4Q (Nov) 4Q (Nov) 4Q (Dec) 1Q (Jan) 1Q (Jan)

Brand Name

Aricept® Quixin® Rythmol® SR Xalatan Accolate® Aromasin® Femara® Lotrel®

Generic name

levofloxacin ophthalmic solution propafenone extended-release

capsule

$2 $106

amlodipine/benazepril

(approved and briefly launched 5/07)

$360

2011 2011 2011 2011 2011 2011 2011 2011 2012 2012

Nasacort AQ® Levaquin® Uroxatral®

Zyprexaand Zyprexa

Zydis

Solodyn® Caduet® Lipitor® Tazorac® Anzemet®

Clarinex & Clarinex-D(planning OTC prior to

1

generic availability)

triamcinolone nasal

spray

(previously approved, not

launched 7/09)

$272

alfuzosin extended-release tablet

olanzapine minocycline extended-release tablet

(previously approved, briefly launched)

$196 Zyprexa: $1,968 Zydis: $156

$588 $362

amlodipine/ atorvastatin

desloratadine and desloratadine/ pseudoephedrine

Clarinex: $217 Clarinex D: $39

Information current as of August 2010. Estimated dates are subject to change due to patent litigation, additional patents, exclusivities…

第1页

你可能喜欢

热门文档

站点地图 | 文档上传 | 侵权投诉 | 手机版
本站所有资源均来自互联网,本站只负责收集和整理,均不承担任何法律责任,如有侵权等其它行为请联系我们.
文档下载 Copyright 2013 doc.guandang.net All Rights Reserved.  -  email